Revance price target raised to $42 from $29 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Revance to $42 from $29 and keeps a Buy rating on the shares. The anlasyt reviewed over 100 social media posts made by both Daxxify injectors and patients across different platforms, which increased the firm’s confidence in Daxxify’s commercial prospects.